An ASO targeting LINC02273 inhibits the formation of the hnRNPL-LINC02273 complex, thereby reducing AGR2 expression and inhibiting BC metastasis in vitro and in vivo (Xiu et al., 2019). Here, AGR2 is linked to breast cancer.